H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Corcept Therapeutics (CORT – Research Report) today and set a price target of $115.00.
Swayampakula Ramakanth’s rating is based on Corcept Therapeutics’ strong financial outlook and promising clinical developments. The company reported robust revenue growth projections for 2025, with expectations of a 33%-41% increase compared to 2024, driven by the sales of Korlym. This optimistic revenue guidance reflects management’s confidence in the continued demand and market penetration of their products.
Additionally, the imminent release of data from the pivotal Phase 3 ROSELLA study, evaluating relacorilant for ovarian cancer treatment, adds to the positive outlook. The study’s dual-primary endpoints, progression-free survival and overall survival, provide multiple opportunities for success, enhancing the potential for regulatory approval. Furthermore, the ongoing growth in Korlym prescriptions and the strategic initiatives to address operational challenges suggest sustained momentum in their core business. These factors collectively underpin the Buy rating, highlighting the company’s potential for significant future growth.
Ramakanth covers the Healthcare sector, focusing on stocks such as Eton Pharmaceuticals, AbSci, and Bicycle Therapeutics. According to TipRanks, Ramakanth has an average return of 6.6% and a 39.24% success rate on recommended stocks.
In another report released on February 24, Canaccord Genuity also maintained a Buy rating on the stock with a $130.00 price target.